[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @fakepharmabro pharma bro pharma bro posts on X about $nvo, $mtsr, $pfe, $vrtx the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::894604683196682241/interactions)  - X Week XXXXXXX +482% - X Month XXXXXXX +499% - X Months XXXXXXX +114% - X Year XXXXXXX +5.80% ### Mentions: XX [#](/creator/twitter::894604683196682241/posts_active)  - X Week XX +286% - X Month XX +140% - X Months XXX +71% - X Year XXX +4.10% ### Followers: XXXXX [#](/creator/twitter::894604683196682241/followers)  - X Week XXXXX +11% - X Month XXXXX +17% - X Months XXXXX +47% - X Year XXXXX +65% ### CreatorRank: XXXXXXX [#](/creator/twitter::894604683196682241/influencer_rank)  ### Social Influence [#](/creator/twitter::894604683196682241/influence) --- **Social category influence** [stocks](/list/stocks) XXXXX% [finance](/list/finance) XXXXX% [cryptocurrencies](/list/cryptocurrencies) XXX% **Social topic influence** [$nvo](/topic/$nvo) 10.34%, [$mtsr](/topic/$mtsr) 10.34%, [$pfe](/topic/$pfe) 10.34%, [$vrtx](/topic/$vrtx) #23, [$5650sh](/topic/$5650sh) 3.45%, [$2125sh](/topic/$2125sh) 3.45%, [$bmy](/topic/$bmy) 3.45%, [investment](/topic/investment) 3.45%, [$argx](/topic/$argx) 3.45%, [$biib](/topic/$biib) XXXX% **Top accounts mentioned or mentioned by** [@mergerpie](/creator/undefined) [@drsprs](/creator/undefined) [@wallstsai](/creator/undefined) [@melvinriskmgmt](/creator/undefined) [@charleslee377](/creator/undefined) [@brwtoovey](/creator/undefined) [@persimmonti](/creator/undefined) [@semodough](/creator/undefined) [@jd4for4](/creator/undefined) [@meadowcapital](/creator/undefined) **Top assets mentioned** [Novo-Nordisk (NVO)](/topic/$nvo) [Metsera, Inc. Common Stock (MTSR)](/topic/$mtsr) [Pfizer, Inc. (PFE)](/topic/$pfe) [Vertex Protocol (VRTX)](/topic/$vrtx) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Biogen Inc (BIIB)](/topic/$biib) [BioMarin Pharmaceutical, Inc. (BMRN)](/topic/$bmrn) [GSK plc (GSK)](/topic/$gsk) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Biohaven Pharmaceutical Holding Company Ltd. (BHVN)](/topic/$bhvn) [Janux Therapeutics, Inc. Common Stock (JANX)](/topic/$janx) [Soleno Therapeutics, Inc. Common Stock (SLNO)](/topic/$slno) [Synthetify (SNY)](/topic/$sny) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [Novartis AG (NVS)](/topic/$nvs) [Incyte Corporation (INCY)](/topic/$incy) [Neurocrine Biosciences, Inc. (NBIX)](/topic/$nbix) [United Therapeutics, Corp. (UTHR)](/topic/$uthr) [Ionis Pharmaceuticals, Inc. Common Stock (IONS)](/topic/$ions) [BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [AbbVie Inc (ABBV)](/topic/$abbv) ### Top Social Posts [#](/creator/twitter::894604683196682241/posts) --- Top posts by engagements in the last XX hours "$NVO offers $56.50/sh + $21.25/sh CVR for $MTSR $PFE" [X Link](https://x.com/fakepharmabro/status/1983836574937969019) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-30T10:01Z 3208 followers, 15.2K engagements "(14/x): $BMY Strategically investing in our growth portfolio brands along with BD are our top priorities. we're focusing on balancing up investments that we need to do in order to drive growth in the growth portfolio as well as to create headroom for additional BD" [X Link](https://x.com/fakepharmabro/status/1983902722504945695) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-30T14:24Z 3209 followers, XXX engagements "(15/x): $ARGX Fourth is where we're starting to think about BD. The company has always looked outside for innovative biology. Typically we found it in academic centers but we're now moving to a stage where we can use the strength of our b/s to also look at other biotechs" [X Link](https://x.com/fakepharmabro/status/1983903567103541414) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-30T14:27Z 3209 followers, 1167 engagements "(16/x): $BIIB we expect to announce at least another one if not two further research stage deals by the end of the year. And I would argue there's never been a better time to be in immunology and I think Biogen is ideally suited to it" [X Link](https://x.com/fakepharmabro/status/1983904661787832389) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-30T14:31Z 3207 followers, 3203 engagements "Ah yes this will end well $PFE mulls suing $MTSR $NVO over topping bid" [X Link](https://x.com/fakepharmabro/status/1983954644914070001) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-30T17:50Z 3208 followers, 26.7K engagements "$PFE $MTSR $NVO" [X Link](https://x.com/fakepharmabro/status/1984359525747732844) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-31T20:39Z 3208 followers, 6419 engagements "(8/x): $RHHBY And we also know we're not done with BD. We can continue to invest in BD and bring in more opportunities that will continue to drive growth also into the future" [X Link](https://x.com/fakepharmabro/status/1983330041359675858) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-29T00:28Z 3210 followers, 3349 engagements "(9/x): $BMRN We estimate that our total firepower is between $X billion to $X billion We're also looking at Phase III pre-commercial and commercial assets because again we think we can add value to all stakeholders with those in our hands" [X Link](https://x.com/fakepharmabro/status/1983332765648203822) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-29T00:39Z 3209 followers, 3908 engagements "(10/x): $GSK I think you should expect that BD will continue tobe a very material contributor to our pipeline with a focus on our I&I and onc on the kind of scale and pace. But we're always going to be looking out at things and review it very very regularly" [X Link](https://x.com/fakepharmabro/status/1983531969691762979) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-29T13:50Z 3210 followers, 2129 engagements "(17/x): $MRK we're not done. We do need to do more. We continue to look across all therapeutic areas. Oncology continues to see a lot of opportunities immunology cardiometabolic and the like. we continue to be focused in that $1-15b rangewilling to go larger" [X Link](https://x.com/fakepharmabro/status/1983909579290300448) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-30T14:51Z 3210 followers, 2900 engagements "XBI has been on a tear the last X months (+33%) but still some notable laggards w/ upcoming catalysts $SPRY (-36%) / 3Q ER $BHVN (-24%) / SCA PDUFA $JANX (-23%) / '007 & '008 data $TECX (-15%) / AZD3427 data $VRTX (-15%) / 3Q ER $SLNO (-13%) / 3Q ER" [X Link](https://x.com/fakepharmabro/status/1982601400577331491) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-27T00:13Z 3210 followers, 15.1K engagements "(3/x): $SNY We have space in our b/swe could afford investing in BD and M&A currently something like 14B 15Bwhat we are looking for is to meet X criteriastrategic fitscientific differentiationand financial return" [X Link](https://x.com/fakepharmabro/status/1983242851329659039) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-28T18:41Z 3210 followers, 26K engagements "(4/x): $REGN Just on whether or not we would use our balance sheet for large deals we certainly have no allergy to doing that if we saw the right opportunity. So it's not a question of philosophy there. It's really a question of what would make sense" [X Link](https://x.com/fakepharmabro/status/1983242853854712069) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-28T18:41Z 3210 followers, 3607 engagements "(5/x): $NVS cash flow remains a strategic priority as it increased further our ability to convert strong core operating income growth and robust free cash flow and gives us the capacity to reinvest in our business organically pursue value-creating bolt-ons like Avidity" [X Link](https://x.com/fakepharmabro/status/1983242856333508657) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-28T18:41Z 3210 followers, 4100 engagements "(6/x): $INCY BD works when you have strong strategic leadership high throughput and a framework for rapidly triaging opportunities and making decisions which requires a skilled search and evaluation teamWe will share more details about our strategic review early next year" [X Link](https://x.com/fakepharmabro/status/1983242859558908017) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-28T18:41Z 3210 followers, 5910 engagements "(7/x): $NBIX we have $2.1B in cash right now no debt. We're profitableof course have flexibility to do share buyback but I would say that our bias is to utilize our capital for business development activities right now focused on driving our own internal initiatives" [X Link](https://x.com/fakepharmabro/status/1983295548770910341) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-28T22:11Z 3210 followers, 7612 engagements "(11/x): $UTHR I'll point out that we are actively engaged in all manner of business development. In fact I can predict that great companies such as Merck Johnson & Johnson or Novartis with strong pulmonary disease franchises will be very keen to partner with us" [X Link](https://x.com/fakepharmabro/status/1983533189592240150) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-29T13:55Z 3210 followers, 11.4K engagements "(12/x): $IONS We do have a strong B/Stop priority for capital allocation is for internal growth. We think that there'sopportunity in our pipeline and behind these existing marketed products and the ones coming to marketcont. to prioritize growth for capital allocation" [X Link](https://x.com/fakepharmabro/status/1983578591993500047) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-29T16:56Z 3210 followers, 2375 engagements "(13/x): $BBIO We're looking across the industry right now. There are several other entities out there that may be deprioritizing rare and orphan disease because investors don't view it as high a priority.we can be a reasonable partner all the way through the life cycle" [X Link](https://x.com/fakepharmabro/status/1983677291747049559) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-29T23:28Z 3210 followers, 2272 engagements "(18/x): $GILD We are looking actively at opportunities across the BD spectrum in all of our areas of strategic interest. That includes liver disease as well as oncology cell therapy broadly virology and immunologylate stage derisked assets" [X Link](https://x.com/fakepharmabro/status/1984032789306736863) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-30T23:00Z 3210 followers, 5018 engagements "(19/x): $ABBV Our BD focus conts. to be on assets that can drive growth in the next decade and beyond. We certainly have the financial wherewithal to pursue late-stage opportunities as well. That's not really a needfocused our efforts on novel MoA and platform technologies" [X Link](https://x.com/fakepharmabro/status/1984306784228532734) [@fakepharmabro](/creator/x/fakepharmabro) 2025-10-31T17:09Z 3210 followers, 1766 engagements "(20/x): $VRTX Our BD strategy is very much in lockstep with our internal innovation strategy. It's all about the SandBox diseases and our approach to R&D high unmet need the biomarkers that translate from bench to bedside as well as targets that are validated" [X Link](https://x.com/fakepharmabro/status/1985519426863497377) [@fakepharmabro](/creator/x/fakepharmabro) 2025-11-04T01:28Z 3210 followers, 1041 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@fakepharmabro pharma bro
pharma bro posts on X about $nvo, $mtsr, $pfe, $vrtx the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXXX +482%
- X Month XXXXXXX +499%
- X Months XXXXXXX +114%
- X Year XXXXXXX +5.80%
Mentions: XX #
- X Week XX +286%
- X Month XX +140%
- X Months XXX +71%
- X Year XXX +4.10%
Followers: XXXXX #
- X Week XXXXX +11%
- X Month XXXXX +17%
- X Months XXXXX +47%
- X Year XXXXX +65%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence stocks XXXXX% finance XXXXX% cryptocurrencies XXX%
Social topic influence $nvo 10.34%, $mtsr 10.34%, $pfe 10.34%, $vrtx #23, $5650sh 3.45%, $2125sh 3.45%, $bmy 3.45%, investment 3.45%, $argx 3.45%, $biib XXXX%
Top accounts mentioned or mentioned by @mergerpie @drsprs @wallstsai @melvinriskmgmt @charleslee377 @brwtoovey @persimmonti @semodough @jd4for4 @meadowcapital
Top assets mentioned Novo-Nordisk (NVO) Metsera, Inc. Common Stock (MTSR) Pfizer, Inc. (PFE) Vertex Protocol (VRTX) Bristol-Myers Squibb Co (BMY) Biogen Inc (BIIB) BioMarin Pharmaceutical, Inc. (BMRN) GSK plc (GSK) Merck & Co., Inc. (MRK) Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Janux Therapeutics, Inc. Common Stock (JANX) Soleno Therapeutics, Inc. Common Stock (SLNO) Synthetify (SNY) Regeneron Pharmaceuticals Inc (REGN) Novartis AG (NVS) Incyte Corporation (INCY) Neurocrine Biosciences, Inc. (NBIX) United Therapeutics, Corp. (UTHR) Ionis Pharmaceuticals, Inc. Common Stock (IONS) BridgeBio Pharma, Inc. Common Stock (BBIO) Gilead Sciences, Inc. (GILD) AbbVie Inc (ABBV)
Top Social Posts #
Top posts by engagements in the last XX hours
"$NVO offers $56.50/sh + $21.25/sh CVR for $MTSR $PFE"
X Link @fakepharmabro 2025-10-30T10:01Z 3208 followers, 15.2K engagements
"(14/x): $BMY Strategically investing in our growth portfolio brands along with BD are our top priorities. we're focusing on balancing up investments that we need to do in order to drive growth in the growth portfolio as well as to create headroom for additional BD"
X Link @fakepharmabro 2025-10-30T14:24Z 3209 followers, XXX engagements
"(15/x): $ARGX Fourth is where we're starting to think about BD. The company has always looked outside for innovative biology. Typically we found it in academic centers but we're now moving to a stage where we can use the strength of our b/s to also look at other biotechs"
X Link @fakepharmabro 2025-10-30T14:27Z 3209 followers, 1167 engagements
"(16/x): $BIIB we expect to announce at least another one if not two further research stage deals by the end of the year. And I would argue there's never been a better time to be in immunology and I think Biogen is ideally suited to it"
X Link @fakepharmabro 2025-10-30T14:31Z 3207 followers, 3203 engagements
"Ah yes this will end well $PFE mulls suing $MTSR $NVO over topping bid"
X Link @fakepharmabro 2025-10-30T17:50Z 3208 followers, 26.7K engagements
"$PFE $MTSR $NVO"
X Link @fakepharmabro 2025-10-31T20:39Z 3208 followers, 6419 engagements
"(8/x): $RHHBY And we also know we're not done with BD. We can continue to invest in BD and bring in more opportunities that will continue to drive growth also into the future"
X Link @fakepharmabro 2025-10-29T00:28Z 3210 followers, 3349 engagements
"(9/x): $BMRN We estimate that our total firepower is between $X billion to $X billion We're also looking at Phase III pre-commercial and commercial assets because again we think we can add value to all stakeholders with those in our hands"
X Link @fakepharmabro 2025-10-29T00:39Z 3209 followers, 3908 engagements
"(10/x): $GSK I think you should expect that BD will continue tobe a very material contributor to our pipeline with a focus on our I&I and onc on the kind of scale and pace. But we're always going to be looking out at things and review it very very regularly"
X Link @fakepharmabro 2025-10-29T13:50Z 3210 followers, 2129 engagements
"(17/x): $MRK we're not done. We do need to do more. We continue to look across all therapeutic areas. Oncology continues to see a lot of opportunities immunology cardiometabolic and the like. we continue to be focused in that $1-15b rangewilling to go larger"
X Link @fakepharmabro 2025-10-30T14:51Z 3210 followers, 2900 engagements
"XBI has been on a tear the last X months (+33%) but still some notable laggards w/ upcoming catalysts $SPRY (-36%) / 3Q ER $BHVN (-24%) / SCA PDUFA $JANX (-23%) / '007 & '008 data $TECX (-15%) / AZD3427 data $VRTX (-15%) / 3Q ER $SLNO (-13%) / 3Q ER"
X Link @fakepharmabro 2025-10-27T00:13Z 3210 followers, 15.1K engagements
"(3/x): $SNY We have space in our b/swe could afford investing in BD and M&A currently something like 14B 15Bwhat we are looking for is to meet X criteriastrategic fitscientific differentiationand financial return"
X Link @fakepharmabro 2025-10-28T18:41Z 3210 followers, 26K engagements
"(4/x): $REGN Just on whether or not we would use our balance sheet for large deals we certainly have no allergy to doing that if we saw the right opportunity. So it's not a question of philosophy there. It's really a question of what would make sense"
X Link @fakepharmabro 2025-10-28T18:41Z 3210 followers, 3607 engagements
"(5/x): $NVS cash flow remains a strategic priority as it increased further our ability to convert strong core operating income growth and robust free cash flow and gives us the capacity to reinvest in our business organically pursue value-creating bolt-ons like Avidity"
X Link @fakepharmabro 2025-10-28T18:41Z 3210 followers, 4100 engagements
"(6/x): $INCY BD works when you have strong strategic leadership high throughput and a framework for rapidly triaging opportunities and making decisions which requires a skilled search and evaluation teamWe will share more details about our strategic review early next year"
X Link @fakepharmabro 2025-10-28T18:41Z 3210 followers, 5910 engagements
"(7/x): $NBIX we have $2.1B in cash right now no debt. We're profitableof course have flexibility to do share buyback but I would say that our bias is to utilize our capital for business development activities right now focused on driving our own internal initiatives"
X Link @fakepharmabro 2025-10-28T22:11Z 3210 followers, 7612 engagements
"(11/x): $UTHR I'll point out that we are actively engaged in all manner of business development. In fact I can predict that great companies such as Merck Johnson & Johnson or Novartis with strong pulmonary disease franchises will be very keen to partner with us"
X Link @fakepharmabro 2025-10-29T13:55Z 3210 followers, 11.4K engagements
"(12/x): $IONS We do have a strong B/Stop priority for capital allocation is for internal growth. We think that there'sopportunity in our pipeline and behind these existing marketed products and the ones coming to marketcont. to prioritize growth for capital allocation"
X Link @fakepharmabro 2025-10-29T16:56Z 3210 followers, 2375 engagements
"(13/x): $BBIO We're looking across the industry right now. There are several other entities out there that may be deprioritizing rare and orphan disease because investors don't view it as high a priority.we can be a reasonable partner all the way through the life cycle"
X Link @fakepharmabro 2025-10-29T23:28Z 3210 followers, 2272 engagements
"(18/x): $GILD We are looking actively at opportunities across the BD spectrum in all of our areas of strategic interest. That includes liver disease as well as oncology cell therapy broadly virology and immunologylate stage derisked assets"
X Link @fakepharmabro 2025-10-30T23:00Z 3210 followers, 5018 engagements
"(19/x): $ABBV Our BD focus conts. to be on assets that can drive growth in the next decade and beyond. We certainly have the financial wherewithal to pursue late-stage opportunities as well. That's not really a needfocused our efforts on novel MoA and platform technologies"
X Link @fakepharmabro 2025-10-31T17:09Z 3210 followers, 1766 engagements
"(20/x): $VRTX Our BD strategy is very much in lockstep with our internal innovation strategy. It's all about the SandBox diseases and our approach to R&D high unmet need the biomarkers that translate from bench to bedside as well as targets that are validated"
X Link @fakepharmabro 2025-11-04T01:28Z 3210 followers, 1041 engagements